Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Leukemia, Promyelocytic, Acute 20Leukemia, Myeloid, Acute 20Myelodysplastic Syndromes 9Multiple Myeloma 9Leukemia 8Pancreatic Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Neuroblastoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thrombocytopenia 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hodgkin Disease 2Hematologic Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Breast Neoplasms 2Blast Crisis 2

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Tretinoin × Clear all
NCT06358677 2026-02-13

FACE

University of Utah

Phase 2 Recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 1 Not yet recruiting
10 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03307148 2020-01-22

STAR_PAC

Barts & The London NHS Trust

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡